Please assess the completion status of the following clinical trial:

Trial Title: Study of Azacitidine to Treat Relapsed or Refractory Multiple Myeloma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* diagnosis of MM as per IMWG criteria~* age greater than 17 years~* have received at least 2 but no more than 4 prior lines of therapy~* have failed to respond to the most recently administered anti-MM therapy or have demonstrably progressive disease as defined by accepted standard criteria~* have a life expectancy of at least 3 months~* ECOG performance status \< 3~* at registration haematological values within the following limits:~  1. absolute neutrophil count (ANC) \> 1.0 x 109/L~ 2. platelet count \> 50 x 109/L unsupported~* At registration biochemical values within the following limits~  1. Bilirubin \< 1.5 x upper limit of normal (ULN) and transaminases \< 2 x ULN unless considered secondary to hepatic myelomatous infiltration~ 2. Serum creatinine \< 0.19mMol/L~* Written informed consent~* Must agree to use adequate contraceptive measures if indicated. Specifically, women of childbearing potential (WOCBP) may participate provided they meet the following conditions:~  1. Agree to use at least 2 effective contraceptive methods throughout the study and for 30 days following the study~ 2. Have a negative serum pregnancy test within 24 hours of commencing on study medication~ 3. Male participants with female partners that are WOCBP must agree to use 2 effective contraceptive methods throughout the study and for 30 days following the study~Exclusion Criteria:~* Patients with monoclonal gammopathy of undetermined significance (MGUS) or indolent/smouldering MM~* Known or suspected hypersensitivity to AZA or mannitol~* Patients whose general condition makes them unsuitable for intensive treatment e.g. significant cardiac or pulmonary disease~* Active infections or other illnesses that precludes chemotherapy administration or patient compliance~* Active viral infection with known human immunodeficiency virus (HIV) or viral hepatitis type B or C~* Pregnant or lactating women

- Gender: ALL
- Minimum Age: 17 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).